

ECONOMIC EVALUATION OF INVESTIGATOR-INITIATED CLINICAL TRIALS CONDUCTED BY NETWORKS

If the results of 25 high-impact clinical trials were implemented in 65% of the eligible Australian patient populations for one year:

\$1.4 billion in better health outcomes for patients


\$580 million in reduced health service costs



\$2
BILLION

**GROSS BENEFIT TO
THE AUSTRALIAN
ECONOMY**

**A RETURN OF
\$5.80 FOR EVERY
\$1 INVESTED IN
NETWORK TRIAL
RESEARCH**



Trial results only needed to be implemented in 11% of the eligible patient populations for benefits to exceed costs

JUST 9% of the \$2 billion gross benefit from the trials in this study was equivalent to all NHMRC funding received by all Australian networks between 2004 and 2014



9%

**A RETURN OF
\$51.10 FOR EVERY
\$1 AWARDED
BY THE NHMRC**

TRIALS CONDUCTED BY NETWORKS:



Identify opportunities for better use of resources



Improve safety and quality



Influence clinical guidelines